Depakote Works for Mania, Not Depression
Depakote (valproate/divalproex sodium) is FDA-approved and effective for treating acute mania in adults, but it is NOT effective for treating bipolar depression in pediatric patients and has limited evidence for depression in adults. 1, 2
Efficacy for Mania
Adult Population
Valproate demonstrates clear antimanic efficacy:
- FDA-approved for acute mania in adults 1
- High-quality evidence shows valproate induces significantly higher response rates versus placebo (45% vs 29%, OR 2.05) 3
- Comparable efficacy to lithium for acute mania (56% vs 62% response rates, no significant difference) 3
- Effective for maintenance treatment, preventing relapse better than placebo (RR 0.68) 4
- Works rapidly when given as a loading dose (25 mg/kg initially, targeting serum levels 85-125 mcg/mL) 5
Pediatric Population
The evidence is notably weaker:
- Efficacy was NOT established in controlled pediatric trials for mania (ages 10-17 years) 2
- No significant difference from placebo in children/adolescents (23% vs 22% response) 3
- Inferior to risperidone in pediatric mania (23% vs 66% response) 3
Efficacy for Depression
The Critical Distinction
Valproate has demonstrated efficacy for treating acute manic symptoms, NOT depressive symptoms 1. The guidelines explicitly state: "most agents only have clearly demonstrated efficacy for treating acute manic symptoms in adults, thus the term antimanic may be a more accurate description. There are considerably fewer data in adults on the treatment of bipolar depression" 1.
Adult Bipolar Depression
The evidence is mixed and limited:
- Small meta-analyses suggest possible benefit (response RR 2.00, remission RR 1.61) 6, but these are based on only 142 total patients across 4 small trials
- Another meta-analysis showed modest effect (SMD -0.35 for depressive symptoms) 7
- One small placebo-controlled trial (n=25) showed superiority over placebo 8
- However, no FDA approval exists for bipolar depression 1
Pediatric Bipolar Depression
No evidence supports valproate for pediatric bipolar depression—the FDA label explicitly states efficacy was not established 2
Important Clinical Considerations
Potential Depressogenic Effect
Emerging evidence suggests high-dose valproate used for acute mania may trigger depressive switches during the continuation phase 9. Consider dose reduction if depressive symptoms emerge after manic episode resolution, as lower doses may be therapeutic for maintenance compared to acute treatment.
Combination Therapy
- Valproate plus lithium is more effective than valproate monotherapy for preventing relapse (RR 0.78) 1, 4
- Combination with atypical antipsychotics (quetiapine, risperidone) shows enhanced efficacy for acute mania 1
Tolerability Profile
- More participants experience adverse events versus placebo (83% vs 75%) 3
- Common side effects: nausea, sedation, upper abdominal pain, increased ammonia, gastritis 2
- Less weight gain and sedation than olanzapine 3
- Requires monitoring: liver function, complete blood counts, pregnancy tests, and serum drug levels every 3-6 months 1
Critical Safety Warnings
- Hepatotoxicity risk, especially in children under age 2 2
- Teratogenicity—contraindicated in pregnancy for non-life-threatening conditions 2
- Risk of polycystic ovary disease in females 1
- Male infertility reports 2
Clinical Algorithm
For Acute Mania (Adults):
- Start valproate 25 mg/kg/day, target serum levels 85-125 mcg/mL
- Expect response within 5-21 days 5
- Consider combination with lithium or atypical antipsychotic for enhanced efficacy
- Monitor liver function, CBC, and drug levels
For Bipolar Depression:
- Do NOT use valproate as first-line 1
- Consider olanzapine-fluoxetine combination (FDA-approved) or lamotrigine 1
- If using valproate off-label in adults, recognize limited evidence base
- Never use in pediatric bipolar depression—no evidence of benefit 2
For Maintenance: